CCCC C4 Therapeutics, Inc.

C4 Therapeutics, Inc. provides new class of targeted protein degradation. It develops Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Cambridge, MA.

$36.65  -1.17 (-3.09%)
As of 11/26/2021 13:00:00 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  10/01/2020
Outstanding shares:  48,625,608
Average volume:  205,766
Market cap:   $1,839,020,495
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    12529R107
ISIN:        US12529R1077
Sedol:      BKX9NQ0
Valuation   (See tab for details)
PE ratio:   -22.37
PB ratio:   4.47
PS ratio:   54.14
Return on equity:   -22.58%
Net income %:   -265.03%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy